The UK and US have announced a significant trade agreement that will keep no duties on UK pharmaceutical shipments going into the US market.
Key Provisions of the Pact
As part of the deal, the UK has agreed to boost funding on drugs through the NHS. This pledge secures that duties on these crucial exports will stay at zero for a duration of the next three years.
This development is in response to recent warnings to hike import taxes on branded drug imports, with figures mentioned as high as 100%.
"This agreement with the United Kingdom reinforces the global environment for innovative medicines and introduces much-needed equity to American-British medicine commerce," a release noted.
Commercial Importance
Drugs are one of the the United Kingdom's largest goods shipped to the America, which is clearly the biggest market for large British pharmaceutical firms.
Statistics indicate that in the 12 months prior to last September, the UK sold medicines totaling over eleven billion pounds to the US. This figure represented nearly one-fifth of total UK exports in that span.
"This agreement secures jobs, increases investment and sets the stage for the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary stated.
Specific NHS Changes
The agreement entails several key commitments from the UK:
- Revised Affordability Limit: The UK will lift the affordability limit at which it considers new therapies to be too expensive by 25%.
- Increased NHS Spending: There is a goal to double overall NHS spending on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The sum drug companies must pay back to the NHS to prevent overspending will be limited at 15%. Last year, refunds were more than twenty percent.
Industry Background
The pact follows a long-running dispute between the sector and the UK government over medicine costs and approval rates.
The disagreement were heightened by claims that American customers were charged several times more for the identical medicines than patients in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been paused or scrapped, while major funding commitments have been directed toward American operations.
The Science Minister publicly accepted that the NHS must increase expenditure on treatments, noting that its budget allocation on drugs had decreased as a percentage of its resources over the previous ten-year period.
